GlassScriptPhysician profile
Jasmeet S Dhaliwal
NPI 1750313771
$2,666.99
in general payments reported to CMS, 2019-2025
24 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $103 · 2021: $207 · 2022: $448 · 2023: $678 · 2024: $422 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $630.45 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Novartis Pharmaceuticals Corporation | $332.32 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $324.80 | 2023-2025 | Cequa |
| Biotissue Holdings INC. | $224.76 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $167.34 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $130.02 | 2022-2025 | Durysta |
| Eyevance Pharmaceuticals LLC | $109.13 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $97.10 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $73.55 | 2022-2024 | Ryzumvi, Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $71.27 | 2019-2023 | Tecnis Simplicity |
| Thea Pharma INC. | $61.51 | 2024-2025 | Iyuzeh |
| Harrow Eye, LLC | $58.77 | 2023-2025 | Vevye |
| Allergan, INC. | $52.27 | 2020-2021 | |
| Abb Con-Cise Optical Group LLC | $51.05 | 2024 | Contact Lens, Spectacle Lenses |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.03 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $40.33 | 2019-2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $38.06 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $37.35 | 2019 | |
| Ocular Therapeutix, INC. | $25.41 | 2019 | |
| Ani Pharmaceuticals, INC. | $20.45 | 2025 | Purified Cortrophin Gel |
| Sight Sciences, INC. | $19.60 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Lumibird Medical INC. | $17.60 | 2025 | |
| Gilead Sciences, INC. | $16.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmeet Dhaliwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.